Business ❯ Healthcare

Biotechnology

Pharmaceuticals Drug Development Clinical Trials Gene Therapy Oncology Research and Development Therapeutics Cell Therapy Regulatory Affairs Immunotherapy

ImmunityBio Investors Face May 26 Deadline in Class Action After FDA Flags Misleading Anktiva Claims

Investor leadership now turns on the court’s choice of lead plaintiff.

Sagimet Prices $175 Million Stock Offering as It Plans U.S. Phase 3 Acne Trial

Ligand to Buy XOMA Royalty for $739 Million

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

Cedar Grove’s Q1 Letter Reaffirms Stock-Picking Focus, Highlights Evolv, The RealReal and Abivax

Atara Biotherapeutics Hit With Investor Class Action as Firms Press May 22 Lead-Plaintiff Deadline

ImmunityBio Faces Investor Suits After FDA Rebuke as Anktiva Sales Jump

ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims

Investor Class Actions Target Atara Over FDA Setbacks to EBVALLO

ADMA Biologics Denies Short-Seller Report as Shares Rebound and Law Firms Launch Probes

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Bionano Sets 2026 Outlook After $8 Million Q4 and Sharper Margins

Kynam Trims Syndax Stake With $8.18 Million Q4 Sale Disclosed in SEC Filing

Azitra Announces Up to $31.4 Million Financing as Shares Surge

Sandisk Jumps as AI Data-Center Demand Tightens NAND Supply and Lifts Outlook

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside

Eli Lilly to Acquire Orna Therapeutics in Up to $2.4 Billion Bet on In Vivo CAR‑T

BD Completes Spin-Off, Combining Biosciences and Diagnostics Unit With Waters

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Moderna Raises 2025 Revenue Forecast, Deepens Cost Cuts as Shares Jump